Meeting
2023 ASCO Annual Meeting
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).
Authors
Hiroki Izumi
National Cancer Center Hospital East, Kashiwa, Japan
Hiroki Izumi , Shingo Matsumoto , Kazumi Nishino , Terufumi Kato , Satoshi Hara , Atsushi Nakamura , Jun Sakakibara-Konishi , Shoichiro Yamamoto , Yuichiro Ohe , Ichiro Nakachi , Shoichi Kuyama , Tomohiro Kato , Masahiro Kodani , Yuji Shibata , Hibiki Udagawa , Tetsuya Sakai , Kaname Nosaki , Yoshitaka Zenke , Kiyotaka Yoh , Koichi Goto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
UMIN000041957
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9097)
DOI
10.1200/JCO.2023.41.16_suppl.9097
Abstract #
9097
Poster Bd #
85
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC).
First Author: Shingo Matsumoto
Poster
2020 ASCO Virtual Scientific Program
Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia.
First Author: Shingo Matsumoto
Poster
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
First Author: Ruchit Shah
Poster
2023 ASCO Annual Meeting
Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRAS and MET in non-small cell lung cancer.
First Author: Alexander Watson